ImaginAb, an Inglewood, CA-based clinical stage biotech company, raised $21m in Series B funding.
The round was led by Mérieux Développement, with participation from Novartis Venture Funds, Cycad Group and Nextech Invest.
The company intends to use the funds to accelerate the development of IAB2M, its lead program in prostate cancer, and continue to expand product pipeline.
Co-founded by CEO Dr. Christian Behrenbruch, ImaginAb engineers antibodies into smaller protein formats optimized for in vivo molecular imaging. Its pipeline, which includes imaging agents for prostate, pancreatic and ovarian cancer, is augmented by approximately 30 collaborations with global pharmaceutical companies for a variety of cancer, immune/inflammatory and neurodegenerative disease targets.
FinSMEs
11/05/2015